Business Context and Reporting Period
This Form 8-K filing by vTv Therapeutics Inc. covers events occurring on April 29, 2019, specifically the 2019 Annual Meeting of Stockholders. The filing also references the company's financial results for the fiscal quarter ended March 31, 2019, which were announced via a press release on May 1, 2019 (attached as Exhibit 99.1).
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not detailed in the body of this 8-K report.
Material Changes and Corporate Actions
The primary material events reported are the outcomes of the Annual Meeting of Stockholders held on April 29, 2019:
- Board of Directors Election: Stockholders elected six nominees to the Board of Directors for terms expiring at the 2020 annual meeting. All nominees received significant "For" votes (ranging from approximately 40.18 million to 40.26 million) with zero "Against" votes.
- Independent Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or risk factors within the text provided. It explicitly states that the information regarding financial results is incorporated by reference from the attached press release and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 1, 2019) for specific Q1 2019 financial results, including revenue, net loss, and cash position.
- Verify the total number of shares outstanding and the percentage of votes cast "For" each director nominee to assess shareholder support levels.
- Confirm the specific terms of the engagement with Ernst & Young LLP for the 2019 fiscal year.
- Check subsequent filings for any updates on the company's clinical trial progress or capital raise activities, as this 8-K does not detail operational milestones.